Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
33.14
+0.97 (+3.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
July 28, 2024
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
Via
Benzinga
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
July 25, 2024
Via
Benzinga
Beam Therapeutics Stock Earns RS Rating Jump To 85
July 24, 2024
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.
Via
Investor's Business Daily
Expert Ratings For Beam Therapeutics
April 23, 2024
Via
Benzinga
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
March 27, 2024
Via
Benzinga
Navigating 4 Analyst Ratings For Beam Therapeutics
February 28, 2024
Via
Benzinga
Why Is Conn’s (CONN) Stock Down 36% Today?
July 24, 2024
Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
July 24, 2024
Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock.
Via
InvestorPlace
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
July 23, 2024
Via
Benzinga
3 Gene Editing Stocks Shaping the Future of Medicine
July 22, 2024
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions
Via
InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
July 18, 2024
Via
Benzinga
Beam Therapeutics Announces Transition of Chief Financial Officer
July 15, 2024
From
Beam Therapeutics
Via
GlobeNewswire
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
July 09, 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge.
Via
InvestorPlace
3 Stocks With the Potential to 10X Your Money
July 09, 2024
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost.
Via
InvestorPlace
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Via
InvestorPlace
Exposures
Product Safety
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
July 03, 2024
These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
June 27, 2024
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects.
Via
InvestorPlace
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
June 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
June 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
May 30, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
May 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
Via
InvestorPlace
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
May 08, 2024
From
Beam Therapeutics
Via
GlobeNewswire
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
May 07, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
April 12, 2024
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO:
Via
Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with...
Via
Benzinga
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
March 26, 2024
Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024
From
Beam Therapeutics
Via
GlobeNewswire
MarketBeat Week in Review – 3/4 – 3/8
March 09, 2024
The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hot
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.